Comparision of Various Biomarkers Between Peripheral and Pulmonary Blood

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-10-13

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Lung cancer is a leading cause of cancer death worldwide. Early diagnosis is linked to a better prognosis. Further, surgical resection at the early stages of non-small cell lung cancer (NSCLC) results in markedly improved survival rates. Computed tomography (CT)- or bronchoscopy-guided needle biopsies are standard definitive diagnostic procedures for lung cancer and are used to obtain tissue for pathological examination. However, these procedures are invasive, difficult to repeat, expensive, and risk exposure to radiation. Conversely, liquid biopsies, such as circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and extracellular vesicles (EVs), are simple and less invasive procedures that can be repeated more frequently than tissue biopsies.

This study is a retrospective blood sample obtained and prospectively comparative analysis of various biomarkers (cancer markers, and exosome markers) derived from peripheral blood and pulmonary venous blood from patients who underwent lung cancer surgery.

And treatment monitoring using biomarkers compare with peripheral and pulmonary blood.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Multicenter Clinical Research for Early Diagnosis of Lung Cancer Using Blood Plasma Derived Exosome

NCT04529915

Lung Cancer

UNKNOWN

Serum Exosomal Long Noncoding RNAs as Potential Biomarkers for Lung Cancer Diagnosis

NCT03830619

Lung Cancer (Diagnosis)

COMPLETED

Prospective Cohort of Diagnostic Bronchoscopy for Peripheral Lung Lesions

NCT05804786

Lung Cancer

RECRUITING

Cell Free DNA for the Diagnosis and Treatment in Early NSCLC

NCT03791034

Non-small Cell Lung Cancer

RECRUITING

Cancer Panel From Blood of Lung Cancer Patients

NCT03235765

Non Small Cell Lung Cancer Metastatic Non Small Cell Lung Cancer Recurrent

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer Diagnosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

frozen blood plasma samples

Analysis of various biomarkers using frozen blood samples

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults with Korean nationality
* Patients who did not receive neoadjuvant therapy before surgery
* Patients not diagnosed with any other cancer before surgery
* Patients who agreed to the consent form for a donation of human materials during surgery

Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No